Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

The study involved 80 patients with severe alopecia areata (AA) who were treated with either oral ruxolitinib or tofacitinib citrate over 6 months, followed by a 3-month follow-up. Patients were assessed monthly using the Severity of Alopecia Tool (SALT) scale to measure hair regrowth. Results showed varying degrees of improvement, categorized from low grade (0-24% improvement) to complete grade responders (100% improvement). The study concluded that both treatments were effective in promoting hair regrowth in patients with severe AA, with statistical significance set at p < 0.05.